npj Breast Cancer (Sep 2021)

Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid

  • Neelima Vidula,
  • Sally Greenberg,
  • Laura Petrillo,
  • Jimmy Hwang,
  • Michelle Melisko,
  • Andrei Goga,
  • Mark Moasser,
  • Mark Magbanua,
  • John W. Park,
  • Hope S. Rugo

DOI
https://doi.org/10.1038/s41523-021-00323-8
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 6

Abstract

Read online

Abstract We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at baseline, and 12 and 24 months of ZOL. Complete DTC response ( 30/mL and CTC > 0.8/mL were significantly associated with recurrence and death. Serial reduction in DTCs occurred. Higher baseline DTC > 30/mL and CTC > 0.8/mL correlated with recurrence and death.